Medical Information
United States

In order to provide you with relevant and meaningful content we need to know more about you.

Please choose the category that best describes you.

Información selecta para pacientes y cuidadores que se encuentra disponible en Español.

This content is intended for U.S. Healthcare Professionals. Would you like to proceed?

If you provide additional keywords, you may be able to browse through our database of Scientific Response Documents.

Our scientific content is evidence-based, scientifically balanced and non-promotional. It undergoes rigorous internal medical review and is updated regularly to reflect new information.

DETROL® LA Clinical Studies (tolterodine tartrate)


DETROL LA Capsules 2 mg were evaluated in 29 patients in a Phase 2 dose-effect study. DETROL LA 4 mg was evaluated for the treatment of overactive bladder with symptoms of urge urinary incontinence and frequency in a randomized, placebo-controlled, multicenter, double-blind, Phase 3, 12-week study. A total of 507 patients received DETROL LA 4 mg once daily in the morning and 508 received placebo. The majority of patients were Caucasian (95%) and female (81%), with a mean age of 61 years (range, 20 to 93 years). In the study, 642 patients (42%) were 65 to 93 years of age. The study included patients known to be responsive to tolterodine immediate release and other anticholinergic medications, however, 47% of patients never received prior pharmacotherapy for overactive bladder. At study entry, 97% of patients had at least 5 urge incontinence episodes per week and 91% of patients had 8 or more micturitions per day.

The primary efficacy assessment was change in mean number of incontinence episodes per week at week 12 from baseline. Secondary efficacy measures included change in mean number of micturitions per day and mean volume voided per micturition at week 12 from baseline.

Patients treated with DETROL LA experienced a statistically significant decrease in number of urinary incontinence per week from baseline to last assessment (week 12) compared with placebo as well as a decrease in the average daily urinary frequency and an increase in the average urine volume per void.

Mean change from baseline in weekly incontinence episodes, urinary frequency, and volume voided between placebo and DETROL LA are summarized in Table 4.

Table 4. 95% Confidence Intervals (CI) for the Difference between DETROL LA (4 mg daily) and Placebo for Mean Change at Week 12 from Baseline*
Treatment Difference, vs. Placebo
(95% Cl)
SD = Standard Deviation.
Intent-to-treat analysis.
1 to 2 patients missing in placebo group for each efficacy parameter.
The difference between DETROL LA and placebo was statistically significant.
Number of incontinence episodes/ week
Mean Baseline
Mean Change from Baseline
–11.8 (SD 17.8)
–6.9 (SD 15.4)
(–6.9, –2.8)
Number of micturitions/day
Mean Baseline
Mean Change from Baseline
–1.8 (SD 3.4)
–1.2 (SD 2.9)
(–1.0, –0.2)
Volume voided per micturition (mL)
Mean Baseline
Mean Change from Baseline
34 (SD 51)
14 (SD 41)
(14, 26)
Did you find an answer to your question? Yes No
Didn’t find what you were looking for? Contact us.
Report Adverse Event